Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Endpoint Management and Adjudication Enhance Clinical Trials Platform

By BiotechDaily International staff writers
Posted on 17 Apr 2013
Endpoint adjudication management embedded within an electronic data capture platform optimizes the endpoint management and adjudication process, providing a collaborative and flexible workflow for all participants. Substantial cost effectiveness is achieved and cycle times reduced with a single, seamless system.

Merge Healthcare Incorporated (Chicago, IL, USA), a provider of clinical systems, recently added endpoint and adjudication management to its eClinical OS platform, providing end-to-end study support for trials of all sizes through a single platform.

“Merge eClinical has extensive experience working with the largest endpoint adjudication coordinating centers in the world. These relationships give us the unique experience to develop an endpoint adjudication module that is powerful, yet flexible enough to meet the complex requirements of all our clients. Merge’s latest enhancements to eClinical OS further our vision for delivering a unified solution for all data capture, processing, and return,” said Zaher El-Assi, general manager, eClinical solutions of Merge. “Through its single, easy-to-use interface, built-in study templates, libraries, and reports, and pay-as-you-go pricing, eClinical OS enables study sponsors and CROs to manage and run studies more efficiently than ever before.”

With Merge eClinical OS’ new Endpoint Adjudication Module, customers can: expedite cycle times with redaction tool and electronic compilation of source documents; auto-compile dossiers from source documents; reduce costs with fewer paper documents to track, ship, and review; Manage paired parallel, expert review and committee workflows; receive instant notifications that enable fast and efficient coordination; access reviewer assignments and dossiers from anywhere, at any time; and lastly, improve data quality through eCRFs and online edit checks.

“We began using eClinical OS towards the end of last year to manage and run our studies,” explained Thomas Engels, vice president of clinical affairs for CardioKinetix, Inc. (Menlo Park, CA, USA) “We’ve already seen enhanced efficiencies and improved productivity across the board, and are excited to begin using the new endpoint adjudication module to accelerate cycle times for adjudicating events.”

As a single, web-based system, Merge eClinical OS has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. With a complete menu of clinical trial capabilities that can be mixed and matched, eClinical OS builds a solid foundation for each trial environment. Merge eClinical OS also has the scalability to grow if a trial increases in size, number, or complexity.

“We are obviously pleased by the positive customer response to eClinical OS,” stated Zaher El-Assi, general manager, eClinical Solutions of Merge. “Customer feedback has been integral to the product design, and I think it reflects a renewed focus on study efficiency. Merge eClinical OS places the control back in the users’ hands, resulting in shorter build times, faster implementation, and more cost effective trial design.”

Related Links:
Merge Healthcare



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

Molecular Pathway Decreases Cell Adhesion and Initiates Metastasis

A recent paper outlined a molecular pathway that enables lung cancer cells to migrate away from the site of the primary tumor and become established in other parts of the body. Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) linked a virtual alphabet soup of genes and their protein products... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.